JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258295

Human ADARB1 (RED1) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ADARB1 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 16 bp deletion in exon4.

View Alternative Names

1700057H01Rik, ADAR2, ADAR2a, ADAR2a L1, ADAR2a L2, ADAR2a L3, ADAR2b, ADAR2c, ADAR2d, ADAR2g, ADARB 1, AW124433, AW558573, Adenosine deaminase, RNA specific, 2, Adenosine deaminase, RNA specific, B1, Adenosine deaminase, RNA specific, B1 (RED1 homolog rat), Adenosine deaminase, RNA specific, B1 (homolog of rat RED1), BB220382, D10Bwg0447e, DRABA2, DRADA2, Double-stranded RNA-specific editase 1, EC 3.5.-.-, Human dsRNA adenosine deaminase DRADA2, Human dsRNA adenosine deaminase DRADA2b, EC 3.5, OTTHUMP00000115341, OTTHUMP00000115342, RED1_HUMAN, RNA editase, RNA editase 1, RNA editing enzyme 1, rat, homolog of, RNA specific adenosine deaminase B1, RNA-editing deaminase 1, RNA-editing enzyme 1, dsRNA adenosine deaminase

1 Images
Sanger Sequencing - Human ADARB1 (RED1) knockout HeLa cell lysate (AB258295)
  • Sanger seq

Unknown

Sanger Sequencing - Human ADARB1 (RED1) knockout HeLa cell lysate (AB258295)

Homozygous : 16 bp deletion in exon4

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 16 bp deletion in exon4.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258295-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ADARB1 knockout HeLa cell lysate", "number":"AB258295-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258295-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
ADARB1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RED1 also known as ADARB1 is a protein involved in RNA editing. It weighs approximately 73 kDa. RED1 mainly expresses itself in the central nervous system but also appears in other tissues. This protein modifies RNA molecules by catalyzing the conversion of adenosine to inosine which can alter the coding potential and metabolism of the RNA it acts upon.
Biological function summary

The protein RED1 functions within RNA editing complexes. It co-operates with other proteins like ADAR1 to carry out its editing role. In particular RED1 affects the regulation of gene expression influencing neuronal function and development in the brain. Through its editing capabilities the protein contributes to the diversity and stability of RNA transcripts.

Pathways

RED1 plays a role in neurotransmission and neurodevelopment pathways. It interacts with other editing proteins in the ADAR family to ensure proper RNA sequence modifications critical for brain function. The editing process that RED1 participates in impacts synaptic transmission important for neuronal communication and neural network formation.

The protein RED1 is associated with neurological disorders. Changes in RED1 expression or mutations can link to conditions such as epilepsy and schizophrenia. Aberrations in RNA editing performed by RED1 might lead to the dysfunction of proteins involved in neuronal signaling. It also connects with proteins like ADAR2 influencing the pathological progress of these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com